Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-mestastic high-risk prostate cancer (vol 100, pg 274, 2007)

被引：0
|
作者：
不详
机构：
来源：
BJU INTERNATIONAL | 2007年 / 100卷 / 02期
关键词：
D O I：
10.1111/j.1464-410X.2007.07094.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：480 / 480
页数：1
相关论文
共 50 条
  • [31] Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial
    Heinzelbecker, Julia
    Spieler, Natalie
    Kuehn, Michael
    Fischer, Claus
    Volkmer, Bjoern
    von Rundstedt, Friedrich
    Albers, Peter
    Becht, Eduard
    Bannowsky, Andreas
    Weber, H. Matthias
    Hofmann, Rainer
    Mueller, Markus
    Langbein, Sigrun
    Steiner, Gabriel
    Retz, Margitta
    Karmradt, Joern
    Wagenpfeil, Gudrun
    Wellek, Stefan
    Lehmann, Jan
    Stoeckle, Michael
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 356e19 - 356e30
  • [32] A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
    Gruenwald, Viktor
    Fendler, Wolfgang P.
    Herrmann, Ken
    Reis, Henning
    Roghmann, Florian
    Rahbar, Kambiz
    Heidenreich, Axel
    Giesel, Frederik
    Niegisch, Guenter
    Hadaschik, Boris A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS352 - TPS352
  • [33] Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
    Winquist, E.
    Chi, K. N.
    Chin, J.
    Goldenberg, L.
    Klotz, L.
    Berry, S.
    Saad, F.
    Perrotte, P.
    Ruether, D.
    Trachtenberg, J.
    Gleave, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Long-Term Follow-Up of HLA-A2+Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
    Perambakam, Supriya
    Xie, Hui
    Edassery, Seby
    Peace, David J.
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,
  • [35] Long-term Follow-up of ECOG E4292: A Phase II Trial of High Dose Radiation with Concurrent 5-Fluorouracil and Cisplatin in Patients with Anal Cancer
    Chakravarthy, A.
    Catalano, P. J.
    Martenson, J. A.
    Mondschein, J. K.
    Wagner, H.
    Schuchter, L. M.
    Mansour, E. G.
    Talamonti, M. S.
    Benson, A. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S27 - S27
  • [36] A PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND TOPOTECAN IN PATIENTS WITH HIGH-RISK MALIGNANCIES UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ST. JUDE LONG-TERM FOLLOW-UP
    Kasow, K. A.
    Barfield, R. C.
    Wrigbt, N. L.
    Li, C.
    Srivastava, D. K.
    Horwitz, E. M.
    Leung, W.
    Woodard, P.
    Bowman, L. C.
    Handgretinger, R.
    Hale, G. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 72 - 73
  • [37] LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF HIGH-DOSE RADIATION WITH CONCURRENT 5-FLUOROURACIL AND CISPLATIN IN PATIENTS WITH ANAL CANCER (ECOG E4292)
    Chakravarthy, A. Bapsi
    Catalano, Paul J.
    Martenson, James. A.
    Mondschein, Joshua K.
    Wagner, Henry
    Mansour, Edward G.
    Talamonti, Mark S.
    Benson, Al Bowen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E607 - E613
  • [38] Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOGS9921 (vol 36, pg 1498, 2018)
    Hussain
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20)
  • [39] Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial
    Guttilla, Andrea
    Bortolus, Roberto
    Giannarini, Gianluca
    Ghadjar, Pirus
    Zattoni, Fabio
    Gnech, Michele
    Palumbo, Vito
    Valent, Francesca
    Garbeglio, Antonio
    Zattoni, Filiberto
    RADIATION ONCOLOGY, 2014, 9
  • [40] Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial
    Andrea Guttilla
    Roberto Bortolus
    Gianluca Giannarini
    Pirus Ghadjar
    Fabio Zattoni
    Michele Gnech
    Vito Palumbo
    Francesca Valent
    Antonio Garbeglio
    Filiberto Zattoni
    Radiation Oncology, 9
12345